Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $10.00

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.00.

A number of research analysts have issued reports on HUMA shares. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, October 10th. TD Cowen reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a report on Friday, September 20th.

Humacyte Price Performance

Shares of HUMA opened at $5.22 on Wednesday. The company has a 50 day moving average price of $5.51 and a 200-day moving average price of $6.12. Humacyte has a fifty-two week low of $2.08 and a fifty-two week high of $9.97. The stock has a market capitalization of $623.01 million, a PE ratio of -4.14 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Equities analysts predict that Humacyte will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds have recently modified their holdings of HUMA. Hartline Investment Corp acquired a new stake in shares of Humacyte in the first quarter valued at about $70,000. Private Advisor Group LLC raised its position in shares of Humacyte by 232.7% in the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after buying an additional 222,144 shares during the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Humacyte in the first quarter valued at about $972,000. Vanguard Group Inc. raised its position in shares of Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares during the last quarter. Finally, Anson Funds Management LP acquired a new stake in shares of Humacyte in the first quarter valued at about $156,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.